Clinical Trials on Metastatic Prostatic Adenocarcinoma

Total 22995 results

Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Imperial College London
Wellcome Trust; Imperial Clinical Trials Unit (ICTU)

Completed

PROState Pathway Embedded Comparative Trial (IP3-PROSPECT)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate Cancer

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Metastatic Malignant Neoplasm in Lymph Node | Prostate Ductal Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
The University of Texas Health Science Center at...

Withdrawn

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients (HIIT PCa)

Metastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
University Hospital, Rouen

Recruiting

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies (OPALE)

Metastatic Prostate Adenocarcinoma

France
Phoenix Molecular Imaging

Completed

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Prostate Cancer | Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD)

Prostate Adenocarcinoma | Metastatic Prostate Adenocarcinoma | Castration-resistant

United States, Brazil
Calibr, a division of Scripps Research

Terminated

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Adenocarcinoma

United States
Hellenic Cooperative Oncology Group
NIPD Genetics

Completed

Tumor Molecular Profiling in Patients With Prostate Cancer

Prostate Cancer | Metastatic Prostate Adenocarcinoma

Greece
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
OHSU Knight Cancer Institute
Astellas Pharma US, Inc.; Oregon Health and Science University

Active, not recruiting

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Duke University
Exelixis

Terminated

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)

Prostate Cancer | Prostate Cancer Adenocarcinoma | Non-Metastatic

United States
Imperial College London
Prostate Cancer UK; Imperial Clinical Trials Unit (ICTU)

Recruiting

Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer (IP4-CHRONOS)

Prostate Cancer | Prostate Adenocarcinoma | Non-metastatic Prostate Cancer

United Kingdom
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Puma Biotechnology, Inc.

Withdrawn

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
László Mangel
E-Group ICT Software Informatikai Zrt.

Recruiting

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Metastatic Castration-resistant Prostate Cancer | Adenocarcinoma of the Prostate

Hungary
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
German Cancer Research Center
University Hospital Freiburg; ABX CRO; Friedrich-Alexander-Universität Erlangen-Nürnberg

Completed

Ga-68-PSMA-11 in High-risk Prostate Cancer

Prostate Cancer | Prostate Cancer Metastatic | High-risk Prostate Cancer | Lymphnode Metastasis

Austria, Germany
University of Utah

Terminated

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)

Stage IV Prostate Cancer | Metastatic Prostatic Adenocarcinoma | Castration-Sensitive Prostate Carcinoma | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
University of Chicago

Active, not recruiting

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Progenics Pharmaceuticals, Inc.

Completed

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer (CONDOR)

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Recurrent | Prostate Cancer Metastatic

United States, Canada
The Netherlands Cancer Institute

Completed

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel (OSTRICh)

Metastasis | Prostate Cancer Metastatic

Netherlands
Cliniques universitaires Saint-Luc- Université...

Completed

Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer. (TFE-TVE)

Metastasis | Prostate Adenocarcinoma

Belgium
Sandy Srinivas

Terminated

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

Urologic Neoplasms | Prostate Cancer | Prostate Cancer Metastatic Disease

United States
HKGepitherapeutics
Kazakh Research Institute of Oncology & Radiology

Withdrawn

Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic

Kazakhstan
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
University Health Network, Toronto

Completed

Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC (SubDueP)

Metastatic Prostate Cancer | Bone Metastasis

Canada
University of Chicago

Recruiting

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
Xiao X. Wei, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Prostate Adenocarcinoma | Hormone Sensitive Prostate Cancer | Metastasis Prostate Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Vadim S Koshkin
Eli Lilly and Company; Prostate Cancer Foundation

Active, not recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate Carcinoma

United States
University of Wisconsin, Madison
Prostate Cancer Foundation; Madison Vaccines, Inc

Completed

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Puerto Rico
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.

Not yet recruiting

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
Rampart Health, L.L.C.

Completed

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Metastatic Prostatic Adenocarcinoma

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Duke University
Memorial Sloan Kettering Cancer Center; University of Wisconsin, Madison

Not yet recruiting

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials (ARCTIC)

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic

Clinical Trials on Metastatic Prostatic Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations